ELTX ELICIO THERAPEUTICS INC
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 7 analyst firms say about ELICIO THERAPEUTICS INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
8 rated views · 9 analyst/firm records · 7 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 4 reports on ELTX from 3 analyst firms in the last 90 days (7 firms in the past year).
Comparing each firm's latest target with its previous one: 1 lowered it and 1 left it unchanged.
No firm's latest available rating differs from its previous one.
Latest observed target change: B. Riley Securities lowered its target from $27.00 (set 10 Jun 2026) to $8.00 on 24 Sep 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| B Riley Securities | Mayank Mamtani | Buy | 24 Sep 2026 | 8.00 USD |
| H.C. Wainwright | Robert Burns | Buy | 26 Oct 2026 | 23.00 USD |
| Jonestrading | Boris Peaker | Hold | 16 Jun 2026 | — |
| Jonestrading | Soumit Roy | Hold | 15 Jun 2026 | — |
| Ladenburg Thalmann | Aydin Huseynov | Buy | 18 Jun 2026 | 12.00 USD |
| Ladenburg Thalmann | Kevin M Degeeter | Buy | 18 Jun 2026 | 10.00 USD |
| Rodman & Renshaw | Michael G King | Buy | 15 Jun 2026 | 16.50 USD |
| Weiss Ratings | Unnamed analyst | — | 27 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:45 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.